Movement Disorders (revue) - Exploration (Accueil)

Index « Keywords » - entrée « Antiparkinson Agents (therapeutic use) »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Antiparkinson Agents (supply & distribution) < Antiparkinson Agents (therapeutic use) < Antiparkinson Agents (toxicity)  Facettes :

List of bibliographic references indexed by Antiparkinson Agents (therapeutic use)

Number of relevant bibliographic references: 592.
[0-20] [0 - 20][0 - 50][20-40]
Ident.Authors (with country if any)Title
000039 (2015) Stanley Fahn [États-Unis]The medical treatment of Parkinson disease from James Parkinson to George Cotzias.
000079 (2015) Stanley Fahn [États-Unis]Reply: Oleh Hornykiewicz's contribution to the l-dopa story.
000176 (2015) Michael Samuel [Royaume-Uni] ; Maria Rodriguez-Oroz ; Angelo Antonini ; Jonathan M. Brotchie ; Kallol Ray Chaudhuri ; Richard G. Brown ; Wendy R. Galpern ; Melissa J. Nirenberg ; Michael S. Okun ; Anthony E. LangManagement of impulse control disorders in Parkinson's disease: Controversies and future approaches.
000193 (2015) Stanley Fahn [États-Unis] ; Werner Poewe [Autriche]Levodopa: 50 years of a revolutionary drug for Parkinson disease.
000195 (2015) Peter A. Lewitt [États-Unis]Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics.
000237 (2015) Andrew J. Lees [Royaume-Uni] ; Eduardo Tolosa ; C Warren OlanowFour pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.
000250 (2015) Ji Hyun Ko [États-Unis] ; Renata P. Lerner ; David EidelbergEffects of levodopa on regional cerebral metabolism and blood flow.
000355 (2015) Oleh Hornykiewicz [Autriche]50 years of levodopa.
000371 (2014) Rupam Borgohain [Inde] ; Jozsef Szasz ; Paolo Stanzione ; Chandrashekhar Meshram ; Mohit H. Bhatt ; Dana Chirilineau ; Fabrizio Stocchi ; Valentina Lucini ; Rodolfo Giuliani ; Emma Forrest ; Patricia Rice ; Ravi AnandTwo-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.
000443 (2014) Fabienne S. Sprenger [Autriche] ; Klaus Seppi ; Elisabeth Wolf ; Werner Poewe [Autriche]Relevance of EARLYSTIM in a tertiary movement disorders center.
000522 (2014) Mathias Toft [Norvège] ; Espen DietrichsMedication costs following subthalamic nucleus deep brain stimulation for Parkinson's disease.
000558 (2014) Elisabeth B. Lucassen [États-Unis] ; Nicholas W. Sterling [États-Unis] ; Eun-Young Lee [États-Unis] ; Honglei Chen [États-Unis] ; Mechelle M. Lewis [États-Unis] ; Lan Kong [États-Unis] ; Xuemei Huang [États-Unis]History of smoking and olfaction in Parkinson’s disease
000562 (2014) Gordon W. Duncan [Royaume-Uni] ; Tien K. Khoo ; Alison J. Yarnall ; John T. O'Brien ; Shirley Y. Coleman ; David J. Brooks ; Roger A. Barker ; David J. BurnHealth-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms.
000591 (2014) Jung Han Yoon [Corée du Sud] ; Jin Soo Lee ; Seok Woo Yong ; Ji Man Hong ; Phil Hyu LeeEndothelial dysfunction and hyperhomocysteinemia in Parkinson's disease: flow-mediated dilation study.
000598 (2014) Peter A. Lewitt [États-Unis] ; F Jacob Huff ; Robert A. Hauser ; Dan Chen ; Dmitri Lissin ; Katie Zomorodi ; Kenneth C. CundyDouble-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease.
000653 (2014) Christian R. Baumann [Suisse] ; Ulrike Held ; Philipp O. Valko ; Miriam Wienecke ; Daniel WaldvogelBody side and predominant motor features at the onset of Parkinson's disease are linked to motor and nonmotor progression.
000658 (2014) Shraddha Sapkota [Canada] ; Myrlene Gee ; Jennifer Sabino ; Derek Emery ; Richard CamicioliAssociation of homocysteine with ventricular dilatation and brain atrophy in Parkinson's disease.
000678 (2014) Danhui Zhang [États-Unis] ; Tanuja Bordia [États-Unis] ; Matthew Mcgregor [États-Unis] ; J. Michael Mcintosh [États-Unis] ; Michael W. Decker [États-Unis] ; Maryka Quik [États-Unis]ABT-089 and ABT-894 Reduce L-Dopa-Induced Dyskinesias in a Monkey Model of Parkinson’s Disease
000701 (2013) Mariah J. Lelos ; Emma L. Lane ; Stephen B. DunnettWhat helps can also hinder: a dissociation in the acute effect of levodopa treatment on motor and cognitive functions.
000719 (2013) Yoshikuni Mizuno [Japon] ; Masahiro Nomoto ; Tomoyoshi Kondo ; Kazuko Hasegawa ; Miho Murata ; Masahiro Takeuchi ; Junji Ikeda ; Takayuki Tomida ; Nobutaka HattoriTransdermal rotigotine in early stage Parkinson's disease: a randomized, double-blind, placebo-controlled trial.
000742 (2013) Jau-Shin Lou [États-Unis] ; Diana M. Dimitrova [États-Unis] ; Richard Hammerschlag [États-Unis] ; John Nutt [États-Unis] ; Elizabeth A. Hunt [États-Unis] ; Ryan W. Eaton [États-Unis] ; Sarah C. Johnson [États-Unis] ; Melanie D. Davis [États-Unis] ; Grace C. Arnold [États-Unis] ; Sarah B. Andrea [États-Unis] ; Barry S. Oken [États-Unis]The effect of expectancy and personality on cortical excitability in Parkinson’s disease

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i -k "Antiparkinson Agents (therapeutic use)" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i  \
                -Sk "Antiparkinson Agents (therapeutic use)" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Antiparkinson Agents (therapeutic use)
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024